Publication:
A meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections

dc.contributor.departmentDepartment of Industrial Engineering
dc.contributor.departmentGraduate School of Health Sciences
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorAkcan, Rüştü Emre
dc.contributor.kuauthorAkyol, Merve
dc.contributor.kuauthorBarçın, Erinç
dc.contributor.kuauthorCan, Füsun
dc.contributor.kuauthorDemirlenk, Yusuf Mert
dc.contributor.kuauthorGönen, Mehmet
dc.contributor.kuauthorGücer, Lal Sude
dc.contributor.kuauthorKalay, Zeynepgül
dc.contributor.kuauthorTanrıöver, Cem
dc.contributor.kuauthorUçku, Duygu
dc.contributor.kuauthorErgönül, Önder
dc.contributor.schoolcollegeinstituteCollege of Engineering
dc.contributor.schoolcollegeinstituteGRADUATE SCHOOL OF HEALTH SCIENCES
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2024-11-09T23:47:26Z
dc.date.issued2022
dc.description.abstractWe aimed to describe the effect of aminoglycosides and tigecycline to reduce the mortality in colistin- and carbapenem-resistant Klebsiella pneumoniae (ColR-CR-Kp) infections. We included the studies with defined outcomes after active or non-active antibiotic treatment of ColR-CR-Kp infections. The active treatment was defined as adequate antibiotic use for at least 3 days (72 h) after the diagnosis of ColR-CR-Kp infection by culture. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement and the checklist of PRISMA 2020 was applied. Crude and adjusted odds ratios (OR) with 95% confidence interval (CI) were calculated and pooled in the random effects model. Adding aminoglycosides to the existing treatment regimen reduced overall mortality significantly (OR 0.34, 95% CI 0.20-0.58). Overall mortality was 34% in patients treated with aminoglycoside-combined regimens and was 60% in patients treated with non-aminoglycoside regimens. Treatment with tigecycline is not found to reduce mortality (OR: 0.76, 95% CI: 0.47-1.23). Our results suggest that aminoglycoside addition to the existing regimen of colistin- and carbapenem-resistant Klebsiella pneumoniae infections reduces mortality significantly.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue5
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume41
dc.identifier.doi10.1007/s10096-022-04429-0
dc.identifier.eissn1435-4373
dc.identifier.issn0934-9723
dc.identifier.scopus2-s2.0-85126518036
dc.identifier.urihttps://doi.org/10.1007/s10096-022-04429-0
dc.identifier.urihttps://hdl.handle.net/20.500.14288/14128
dc.identifier.wos770497800002
dc.keywordsMeta-analysis
dc.keywordsAminoglycosides
dc.keywordsGentamicin
dc.keywordsAmikacin
dc.keywordsTigecyclines
dc.keywordsCombined regimen
dc.keywordsColistin- and carbapenem-resistant klebsiella pneumoniae
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofEuropean Journal of Clinical Microbiology and Infectious Diseases
dc.subjectInfectious diseases
dc.subjectMicrobiology
dc.titleA meta-analysis for the role of aminoglycosides and tigecyclines in combined regimens against colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorDemirlenk, Yusuf Mert
local.contributor.kuauthorGücer, Lal Sude
local.contributor.kuauthorUçku, Duygu
local.contributor.kuauthorTanrıöver, Cem
local.contributor.kuauthorAkyol, Merve
local.contributor.kuauthorKalay, Zeynepgül
local.contributor.kuauthorBarçın, Erinç
local.contributor.kuauthorAkcan, Rüştü Emre
local.contributor.kuauthorCan, Füsun
local.contributor.kuauthorGönen, Mehmet
local.contributor.kuauthorErgönül, Mehmet Önder
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1GRADUATE SCHOOL OF HEALTH SCIENCES
local.publication.orgunit1College of Engineering
local.publication.orgunit2Department of Industrial Engineering
local.publication.orgunit2School of Medicine
local.publication.orgunit2Graduate School of Health Sciences
relation.isOrgUnitOfPublicationd6d00f52-d22d-4653-99e7-863efcd47b4a
relation.isOrgUnitOfPublication2f870f28-12c9-4b28-9465-b91a69c1d48c
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd6d00f52-d22d-4653-99e7-863efcd47b4a
relation.isParentOrgUnitOfPublication8e756b23-2d4a-4ce8-b1b3-62c794a8c164
relation.isParentOrgUnitOfPublication4c75e0a5-ca7f-4443-bd78-1b473d4f6743
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery8e756b23-2d4a-4ce8-b1b3-62c794a8c164

Files